Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition
Executive Summary
FTC Acting Chairman Ohlhausen predicts agency will continue to focus on competition issues involving barriers to generics but says 'we need to learn more about how these markets are working today.'
You may also be interested in...
REMS Barriers: US FDA Takes 'Foundational Step' To Improve Generic Access
Generic firms might be able to purchase branded drugs for bioequivalence studies from Europe under concepts that FDA is considering. Commissioner Gottlieb says FDA may allow generic firms to seek wavier of shared REMS to avoid protracted negotiations.
Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling
Only 14 of the 170 brand-generic patent suit settlements in US during FY 2015 potentially involve payments to delay generics; number drops to 5 when payments for litigation fees are excluded.
Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.